{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:13:14Z","timestamp":1785928394980,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031B0459"],"award-info":[{"award-number":["031B0459"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00262-019-02438-1","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T20:03:01Z","timestamp":1575489781000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1\/tryptophan 2,3-dioxygenase expression"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-794X","authenticated-orcid":false,"given":"Richard","family":"Klar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hinterwimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jaschinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"2438_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet Lond Engl"},{"key":"2438_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"2438_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"2438_CR4","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove C, Pilotte L, Th\u00e9ate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269\u20131274. https:\/\/doi.org\/10.1038\/nm934","journal-title":"Nat Med"},{"key":"2438_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz CA, Litzenburger UM, Sahm F et al (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478:197\u2013203. https:\/\/doi.org\/10.1038\/nature10491","journal-title":"Nature"},{"key":"2438_CR6","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1046\/j.1365-2567.2002.01526.x","volume":"107","author":"GK Lee","year":"2002","unstructured":"Lee GK, Park HJ, Macleod M et al (2002) Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 107:452\u2013460","journal-title":"Immunology"},{"key":"2438_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/ni.1912","volume":"11","author":"L Apetoh","year":"2010","unstructured":"Apetoh L, Quintana FJ, Pot C et al (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11:854\u2013861. https:\/\/doi.org\/10.1038\/ni.1912","journal-title":"Nat Immunol"},{"key":"2438_CR8","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu X, Shin N, Koblish HK et al (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115:3520\u20133530. https:\/\/doi.org\/10.1182\/blood-2009-09-246124","journal-title":"Blood"},{"key":"2438_CR9","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1021\/acs.jmedchem.7b00974","volume":"60","author":"S Crosignani","year":"2017","unstructured":"Crosignani S, Bingham P, Bottemanne P et al (2017) Discovery of a novel and selective indoleamine 2,3-dioxygenase (IDO-1) inhibitor 3-(5-fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271\/PF-06840003) and its characterization as a potential clinical candidate. J Med Chem 60:9617\u20139629. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00974","journal-title":"J Med Chem"},{"key":"2438_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1021\/acsmedchemlett.7b00427","volume":"9","author":"Z Pei","year":"2018","unstructured":"Pei Z, Mendonca R, Gazzard L et al (2018) Aminoisoxazoles as potent inhibitors of tryptophan 2,3-dioxygenase 2 (TDO2). ACS Med Chem Lett 9:417\u2013421. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00427","journal-title":"ACS Med Chem Lett"},{"key":"2438_CR11","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","volume":"23","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, O\u2019Dwyer PJ, Clark J et al (2017) First-in-human phase 1 study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 Epacadostat (INCB024360) in patients with advanced solid malignancies. Clin Cancer Res Off J Am Assoc Cancer Res 23:3269\u20133276. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2272","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2438_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9602","author":"TC Mitchell","year":"2018","unstructured":"Mitchell TC, Hamid O, Smith DC et al (2018) Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE-037). J Clin Oncol Off J Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.78.9602(JCO2018789602)","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2438_CR13","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1200\/JCO.2017.35.15_suppl.3003","volume":"35","author":"RP Perez","year":"2017","unstructured":"Perez RP, Riese MJ, Lewis KD et al (2017) Epacadostat plus nivolumab in patients with advanced solid tumors: preliminary phase I\/II results of ECHO-204. J Clin Oncol 35:3003. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3003","journal-title":"J Clin Oncol"},{"key":"2438_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2018.36.15_suppl.108","volume":"36","author":"GV Long","year":"2018","unstructured":"Long GV, Dummer R, Hamid O et al (2018) Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301\/KEYNOTE-252 study. J Clin Oncol 36:108. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.108","journal-title":"J Clin Oncol"},{"key":"2438_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.bi.54.070185.002055","volume":"54","author":"F Eckstein","year":"1985","unstructured":"Eckstein F (1985) Nucleoside phosphorothioates. Annu Rev Biochem 54:367\u2013402. https:\/\/doi.org\/10.1146\/annurev.bi.54.070185.002055","journal-title":"Annu Rev Biochem"},{"key":"2438_CR16","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1093\/nar\/gkp841","volume":"38","author":"CA Stein","year":"2010","unstructured":"Stein CA, Hansen JB, Lai J et al (2010) Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38:e3\u2013e3. https:\/\/doi.org\/10.1093\/nar\/gkp841","journal-title":"Nucleic Acids Res"},{"key":"2438_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-1-4939-2727-2_9","volume-title":"Gene therapy of solid cancers: methods and protocols","author":"F Jaschinski","year":"2015","unstructured":"Jaschinski F, Korhonen H, Janicot M (2015) Design and selection of antisense oligonucleotides targeting transforming growth factor beta (TGF-\u03b2) isoform mRNAs for the treatment of solid tumors. In: Walther W, Stein U (eds) Gene therapy of solid cancers: methods and protocols. Springer, New York, pp 137\u2013151"},{"key":"2438_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0545-9","author":"AS Kashyap","year":"2019","unstructured":"Kashyap AS, Thelemann T, Klar R et al (2019) Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. J Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-019-0545-9","journal-title":"J Immunother Cancer"},{"key":"2438_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1479-5876-9-151","volume":"9","author":"B Beck","year":"2011","unstructured":"Beck B, D\u00f6rfel D, Lichtenegger FS et al (2011) Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J Transl Med 9:151. https:\/\/doi.org\/10.1186\/1479-5876-9-151","journal-title":"J Transl Med"},{"key":"2438_CR20","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J (2017) SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinform Oxf Engl 33:2413\u20132415. https:\/\/doi.org\/10.1093\/bioinformatics\/btx162","journal-title":"Bioinform Oxf Engl"},{"key":"2438_CR21","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2018","unstructured":"R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna"},{"key":"2438_CR22","first-page":"285","volume":"3","author":"S Loewe","year":"1953","unstructured":"Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3:285\u2013290","journal-title":"Arzneimittelforschung"},{"key":"2438_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ctrv.2014.06.012","volume":"40","author":"D McDermott","year":"2014","unstructured":"McDermott D, Lebb\u00e9 C, Hodi FS et al (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 40:1056\u20131064. https:\/\/doi.org\/10.1016\/j.ctrv.2014.06.012","journal-title":"Cancer Treat Rev"},{"key":"2438_CR24","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517\u20132526. https:\/\/doi.org\/10.1056\/NEJMoa1104621","journal-title":"N Engl J Med"},{"key":"2438_CR25","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384. https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"key":"2438_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"2438_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/0003-9861(91)90142-6","volume":"291","author":"SG Cady","year":"1991","unstructured":"Cady SG, Sono M (1991) 1-Methyl-dl-tryptophan, beta-(3-benzofuranyl)-dl-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-dl-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 291:326\u2013333","journal-title":"Arch Biochem Biophys"},{"key":"2438_CR28","doi-asserted-by":"crossref","unstructured":"Papadopoulos K, Eder P, Piha-Paul SA et al (2019) First-in-human phase I study of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase-1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid malignancies. In: AACR. Atlanta, p abstract no. CT011\/6","DOI":"10.1158\/1538-7445.SABCS18-CT011"},{"key":"2438_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/2326-6066.CIR-14-0137","volume":"3","author":"I Th\u00e9ate","year":"2015","unstructured":"Th\u00e9ate I, van Baren N, Pilotte L et al (2015) Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol Res 3:161\u2013172. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0137","journal-title":"Cancer Immunol Res"},{"key":"2438_CR30","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1158\/1078-0432.CCR-17-0120","volume":"23","author":"L Zhai","year":"2017","unstructured":"Zhai L, Ladomersky E, Lauing KL et al (2017) Infiltrating T cells increase IDO1 expression in glioblastoma and contribute to decreased patient survival. Clin Cancer Res 23:6650\u20136660. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0120","journal-title":"Clin Cancer Res"},{"key":"2438_CR31","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002754","author":"Y Kiyozumi","year":"2018","unstructured":"Kiyozumi Y, Baba Y, Okadome K et al (2018) IDO1 expression is associated with immune tolerance and poor prognosis in patients with surgically resected esophageal cancer. Ann Surg. https:\/\/doi.org\/10.1097\/SLA.0000000000002754","journal-title":"Ann Surg"},{"key":"2438_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nm1196","volume":"11","author":"AJ Muller","year":"2005","unstructured":"Muller AJ, DuHadaway JB, Donover PS et al (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312\u2013319. https:\/\/doi.org\/10.1038\/nm1196","journal-title":"Nat Med"},{"key":"2438_CR33","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/0008-5472.CAN-06-2925","volume":"67","author":"D-Y Hou","year":"2007","unstructured":"Hou D-Y, Muller AJ, Sharma MD et al (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67:792\u2013801. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2925","journal-title":"Cancer Res"},{"key":"2438_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2051-1426-2-3","volume":"2","author":"S Spranger","year":"2014","unstructured":"Spranger S, Koblish HK, Horton B et al (2014) Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2:3. https:\/\/doi.org\/10.1186\/2051-1426-2-3","journal-title":"J Immunother Cancer"},{"key":"2438_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS, Norris D, Yu R, Bennett CF (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351. https:\/\/doi.org\/10.1016\/j.addr.2015.01.008","journal-title":"Adv Drug Deliv Rev"},{"key":"2438_CR36","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.4049\/jimmunol.1201449","volume":"190","author":"J Yu","year":"2013","unstructured":"Yu J, Du W, Yan F et al (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO Expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190:3783\u20133797. https:\/\/doi.org\/10.4049\/jimmunol.1201449","journal-title":"J Immunol"},{"key":"2438_CR37","doi-asserted-by":"publisher","first-page":"17073","DOI":"10.1073\/pnas.0806173105","volume":"105","author":"AJ Muller","year":"2008","unstructured":"Muller AJ, Sharma MD, Chandler PR et al (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci 105:17073\u201317078. https:\/\/doi.org\/10.1073\/pnas.0806173105","journal-title":"Proc Natl Acad Sci"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02438-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T02:16:05Z","timestamp":1606961765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02438-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02438-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,4]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Richard Klar, Sven Michel, Monika Schell, Lisa Hinterwimmer and Frank Jaschinski are employed by Secarna. Richard Klar and Frank Jaschinski are holding patents for IDO1 and TDO2 ASOs, Sven Michel is holding a patent for TDO2 ASOs. Alfred Zippelius received research funding from Secarna Munich.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Leukapheresis from healthy individuals was collected after informed consent following requirements of the local ethical board and principles of the Helsinki Declaration. The study was approved by the ethics commission of the Technical University of Munich (ethics commission reference: 329\/16 S, study approval date: 9-19-2016).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Healthy donors consented in written form that their personal information was anonymized after leukapheresis and their PBMC were used to investigate the effect of antisense oligonucleotide-mediated knockdown of immunosuppressive factors in vitro.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"EFO-21 (purchased from DSMZ), SKOV-3 (purchased from ATCC), MDA-MB-453 (purchased from ATCC) and A-172 (purchased from ATCC) cells were used in this study. Authentication of cell lines was not required as cells were purchased from professional vendors and master cell banks were generated shortly after taking the original vials into culture. Cells were kept in culture for a maximum time of 3\u00a0weeks to minimize the risk of contaminations.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note on previous publication"}}]}}